Investment analysts at StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ – Get Free Report) in a report issued on Saturday. The brokerage set a “hold” rating on the medical research company’s stock.
Enzo Biochem Price Performance
NYSE ENZ opened at $0.66 on Friday. Enzo Biochem has a one year low of $0.63 and a one year high of $1.44. The company’s 50-day simple moving average is $0.88 and its two-hundred day simple moving average is $1.04.
Enzo Biochem (NYSE:ENZ – Get Free Report) last announced its earnings results on Monday, December 16th. The medical research company reported ($0.05) EPS for the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.
Hedge Funds Weigh In On Enzo Biochem
About Enzo Biochem
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Featured Articles
- Five stocks we like better than Enzo Biochem
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- What is Insider Trading? What You Can Learn from Insider Trading
- Oilfield Leader SLB: An AI Name You Need to Know
- Comparing and Trading High PE Ratio Stocks
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.